Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs YieldMax MSTR Option Income Strategy ETF (MSTY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs YieldMax MSTR Option Income Strategy ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while YieldMax MSTR Option Income Strategy ETF trades at $12.63. The key difference: Alnylam Pharmaceuticals, Inc. is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ALNY | MSTY | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $491.22 | $114.30 |
52-Week Low | $278.09 | $11.55 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
MSTY trades at $12.83, up 0.79% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF maintains a high distribution schedule, paying weekly dividends, though recent news highlights concerns over uncapped losses and NAV erosion. Support is clustered around $12-$13, with resistance just above the current price.
Outlook remains cautious due to structural risks from the covered-call strategy capping upside. High yield appeals to income seekers, but total return depends on preserving capital. Key risks include Strategy stock volatility and return-of-capital distributions undermining long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →
